Novo Nordisk Stock Falls After Weight Loss Drug Data

Novo Nordisk's stock dropped significantly after new data showed its experimental weight-loss drug Cagrisema was less effective than Eli Lilly's tirzepatide.

23 Feb, 09:49 — 23 Feb, 09:49

Post Share

ℹOnly 1 source covers this story

Read at source (1 outlet)

berlingske7h ago

Novo Nordisk-aktie falder efter ny data om vægttabshåb

Cagrisema viser et lavere vægttab end Eli Lillys aktive stof tirzepatid i et nyt studie. Novo-aktien falder.

Read full article →

PERSPECTA

PERSPECTA

Novo Nordisk Stock Falls After Weight Loss Drug Data

Read at source (1 outlet)

Novo Nordisk-aktie falder efter ny data om vægttabshåb

Related Stories

Tourism arrivals from Serbia to Cyprus saw record increase in 2025

Creche Worker Loses Case After Claiming Discrimination Due to Height

Fire Extinguished at Sij Metal Ravne Forge in Slovenia

Lidl Stores in Serbia Announce New Opening Hours

PERSPECTA